A Randomized, Placebo Controlled, Double Blind, Dose Escalating, Crossover, Safety and Pharmacokinetic Study of AX-024.HCl in Healthy Male Subjects

Trial Profile

A Randomized, Placebo Controlled, Double Blind, Dose Escalating, Crossover, Safety and Pharmacokinetic Study of AX-024.HCl in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs AX 024 (Primary)
  • Indications Asthma; Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Artax Biopharma
  • Most Recent Events

    • 13 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 24 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top